BACKGROUND: The analysis and interpretation of data generated from patient-derived clinical samples relies on access to high-quality bioinformatics resources. These are maintained and updated by expert curators extracting knowledge from unstructured ...
BACKGROUND: Because Alzheimer's Disease (AD) has very complicated pattern changes, it is difficult to evaluate it with a specific factor. Recently, novel machine learning methods have been applied to solve limitations.
BACKGROUND: Alzheimer's disease is characterized by a progressive pattern of cognitive and functional impairment, which ultimately leads to death. Computational approaches have played an important role in the context of drug discovery for anti-Alzhei...
Advances in experimental medicine and biology
Jan 1, 2020
There has always been a need for discovering efficient and dependable Alzheimer's disease (AD) diagnostic biomarkers. Like the majority of diseases, the earlier the diagnosis, the most effective the treatment. (Semi)-automated structural magnetic res...
BACKGROUND: Gene Ontology (GO) is a major bioinformatic resource used for analysis of large biomedical datasets, for example from genome-wide association studies, applied universally across biological fields, including Alzheimer's disease (AD) resear...
BACKGROUND: Several studies investigated clinical and instrumental differences to make diagnosis of dementia in general and in Alzheimer's disease (AD) in particular with the aim to classify, at the individual level, AD patients and healthy controls ...
The journal of prevention of Alzheimer's disease
Jan 1, 2020
The neuropsychological scores and Functional Activities Questionnaire (FAQ) are significant to measure the cognitive and functional domain of the patients affected by the Alzheimer's Disease. Further, there are standardized dataset available today th...
BACKGROUND: In this study, we used a convolutional neural network (CNN) to classify Alzheimer's disease (AD), mild cognitive impairment (MCI), and normal control (NC) subjects based on images of the hippocampus region extracted from magnetic resonanc...
BACKGROUND: The ideal participants for Alzheimer's disease (AD) clinical trials would show cognitive decline in the absence of treatment (i.e., placebo arm) and also would be responsive to the therapeutic intervention being studied (i.e., drug arm). ...
The journal of applied laboratory medicine
Jan 1, 2020
BACKGROUND: Accurate diagnosis of Alzheimer disease (AD) involving less invasive molecular procedures and at reasonable cost is an unmet medical need. We identified a serum miRNA signature for AD that is less invasive than a measure in cerebrospinal ...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.